Navigation Links
Accentia Biopharmaceuticals Announces Favorable Interim Blinded,Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial,for Chronic Sinusitis

tients who reported complete resolution of one cardinal symptom there was an average improvement in endoscopy scores of 12%. In patients who reported resolution of both cardinal symptoms there was an average improvement in endoscopy scores of 23%."

The clinical trial has reached approximately 80% enrollment and the Company believes it will finish enrollment of the 300 patients required for randomization during the summer. Unblinded top-line results for all patients are expected to be available before the end of the year.

Members of the investment community, the media, and other interested parties can access the PowerPoint presentation and an audio webcast by visiting Accentia's homepage at www.accentia.net, or for audio only, http://www.wsw.com/webcast/jeff18/abpi. The PowerPoint presentation and audio will be available and archived on Accentia's website for 90 days.

About Accentia Biopharmaceuticals, Inc.

Accentia Biopharmaceuticals, Inc. and its subsidiaries (collectively referred to as the "Company" or "Accentia") is a vertically integrated biopharmaceutical company focused on the development and commercialization of drug candidates that are in late-stage clinical development and typically are based on active pharmaceutical ingredients that have been previously approved by the FDA for other indications. Usually these drug candidates can access the accelerated 505(b)(2) regulatory approval pathway, which is generally less time-consuming and less expensive than the typical 505(b)(1) pathway that must be used for new chemical entities. The Company's lead product candidate is SinuNase(TM), a novel application and formulation of a known therapeutic to treat chronic rhinosinusitis. SinuNase has been granted Fast Track status by the FDA and it is currently in a pivotal Phase 3 clinical trial. During this fiscal year, the Company also plans to file an Investigative New Drug (IND) for a pivotal Phase 3 clinical trial of Revimmune, to treat nume
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Accentia Biopharmaceuticals Scientific Presentations Demonstrate Increasing Acceptance of Fungal Etiology of Chronic Sinusitis at the Annual Meeting of the American Academy of Allergy, Asthma, and Immunology
2. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
3. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia
4. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Mechanism of Action and Clinical Activity of Sulonex(TM) (sulodexide oral gelcap) at the Upcoming American Diabetes Association 67th Scientific Sessions in Chicago, Illinois
5. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
6. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
8. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
9. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone

Post Your Comments:
(Date:11/6/2009)... , BOTHELL, Wash., Nov. 6 /PRNewswire-FirstCa...rted financial results for the three and nine mont...rner, SCOLR Pharma,s President and CEO, said, "We ...ng our 12-hour ibuprofen formulation. Several pote...s in time, personnel and external resources as the...
(Date:11/6/2009)... , ST. LOUIS, Nov. 6 /PRNewswire-FirstCall/ -...continued to depress sales for Allied Healthcare P...nding September 30, 2009. ,, Sales declines pus...oss for the quarter was about $745,000, or negativ...year earlier of about $208,000, or 3 cents per sha...
(Date:11/6/2009)... , WILMINGTON, Mass., Nov. 6 /PRNewswire-Firs...aq GM: DUSA), a dermatology company that is develo...erapy (PDT) and other products focused on patients...oman, President and Chief Executive Officer, will ...n Ford Investor Summit 2009 on Tuesday, November 1...
Breaking Medicine Technology:SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results 2SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results 3SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results 4SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results 5SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results 6SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results 7SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results 8SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results 9Recession Continues to Depress Sales at Allied Healthcare Products 2Recession Continues to Depress Sales at Allied Healthcare Products 3Recession Continues to Depress Sales at Allied Healthcare Products 4Recession Continues to Depress Sales at Allied Healthcare Products 5Recession Continues to Depress Sales at Allied Healthcare Products 6First Potential Lupus Specific Treatment in Sight 4744 1First Potential Lupus Specific Treatment in Sight 4744 2First Potential Lupus Specific Treatment in Sight 4744 3BD PEPFAR Lab Strengthening Initiative Marks Progress in Fight Against HIV AIDS and TB in Sub Saharan Africa 52057 1BD PEPFAR Lab Strengthening Initiative Marks Progress in Fight Against HIV AIDS and TB in Sub Saharan Africa 52057 2BD PEPFAR Lab Strengthening Initiative Marks Progress in Fight Against HIV AIDS and TB in Sub Saharan Africa 52057 3BD PEPFAR Lab Strengthening Initiative Marks Progress in Fight Against HIV AIDS and TB in Sub Saharan Africa 52057 4The Biggest Loser Confirms Talent6 as a Reality TV Heavyweight 52052 1The Biggest Loser Confirms Talent6 as a Reality TV Heavyweight 52052 2The Biggest Loser Confirms Talent6 as a Reality TV Heavyweight 52052 3
(Date:11/7/2009)... Catholics have a responsibility to vigorously opp...us quo." ,, WASHINGTON, Nov. 7 /PRNewswire-...ie Brown released the following statement on the n...er Nancy Pelosi,s Affordable Health Care for Ameri...ng the status quo for abortion is voted upon. ,...
(Date:11/7/2009)...that all youth will rebel, expert says , ,...re likely to behave badly if their parents expect ...o believe they are simply being realistic might ac...Christy Buchanan, a psychology professor at Wake F...in a university news release. "Negative expectatio...
(Date:11/7/2009)... A new foot spray from Greensations fights pain an...ers and caffeine. ThermaFeet targets foot pain and...o contains Black Walnut, Goldenseal, Vitamin C and...chenectady, NY (PRWEB) November 7, 2009 -- A new f...ses circulation with the power of hot peppers and ...
(Date:11/6/2009)... 6 The Leukemia & Lymphoma Society (LLS) ...p; Get program, which in its first two campaigns t...million to support LLS,s blood cancer research fun..., During the campaign, taking place from November ...0% discount coupons participants can use (in-sto...
(Date:11/6/2009)...undreds of Thousands of Idahoans Struggling with H...e Premiums ,, BOISE, Idaho, Nov. 6 As the deb...h and the House readies to vote on critical health... is calling on Idaho,s U.S. Representatives to sup...Care for America Act (H.R. 3962), which will close...
Breaking Medicine News(10 mins):Health News:Statement Regarding Cardinal Rigali's Memo Protecting the 'Status Quo' On Life 2Health News:Bad-Behaving Teens May Be Living Up to Expectations 2Health News:Hot Peppers and Caffeine Relieve Painful Feet, Toe Fungus and Foot Odor 2Health News:Get a Jump on Your Holiday Shopping and Give Two Gifts This Season: One to Your Loved Ones and One to People Battling Blood Cancer 2Health News:AARP Calls On Idaho's U.S. Reps To Back House Health Care Reform Bill 2
...ry Endorses Competition in the Durable Medical ...LE, April 21 Seattle law firm Williams Kastner,se... in a business,litigation case involving claims of...n, Warren and Ruth Ann Hall and Halls,Drug Center,...
...ewswire-FirstCall/ .- Perrigo Company,(Nasdaq: PR...breviated New,Drug Application (ANDA) for over-the...% and Suppository, 1.2g, a generic version of Moni... 1 Combination Pack (miconazole nitrate vaginal cr...
...rst quarter highlights:, -- Record quarterly net ... and 11.5% sequentially, -- Record net income, ...0 per share, up 12.5% over the same period las... First Quarter ...
...Darwin,Professional Underwriters, Inc. (Darwin) (N...ase its first quarter 2008 financial results on Mo...s the company,s first quarter,2008 financial resul...live webcast of Darwin,s earnings conference call ...
...ricans Have Parkinson,s Disease, Roughly ... April 21 Accolade, a Texas-based home,healthcare...rkinson,s,Awareness Month, in hopes of driving awa...aining independence., According to the National P...
...psey join MDS Board, TORONTO, April 21 /PRNewswir...eading provider of products and services to the gl...r. Gregory Spivy, Partner at,ValueAct Capital, and...nd Bill and look forward to benefiting from the,br...
Other Medicine News:Health News:Perrigo Confirms Patent Challenge of Monistat(R) 1 Combination Pack 2Health News:Perrigo Confirms Patent Challenge of Monistat(R) 1 Combination Pack 3Health News:Albemarle Reports Record Quarterly Net Sales and Operating Results 2Health News:Albemarle Reports Record Quarterly Net Sales and Operating Results 3Health News:Albemarle Reports Record Quarterly Net Sales and Operating Results 4Health News:Albemarle Reports Record Quarterly Net Sales and Operating Results 5Health News:Albemarle Reports Record Quarterly Net Sales and Operating Results 6Health News:Albemarle Reports Record Quarterly Net Sales and Operating Results 7Health News:Albemarle Reports Record Quarterly Net Sales and Operating Results 8Health News:Albemarle Reports Record Quarterly Net Sales and Operating Results 9Health News:Albemarle Reports Record Quarterly Net Sales and Operating Results 10Health News:Darwin to Announce First Quarter 2008 Financial Results 2Health News:April is National Parkinson's Disease Awareness Month 2Health News:April is National Parkinson's Disease Awareness Month 3Health News:MDS Appoints Two New Directors 2Health News:MDS Appoints Two New Directors 3
COCOON Disposable Upper Torso - Arms In
COCOON Disposable Lower Torso
COCOON Disposable Upper Torso - Arms Out with face shield and tape
COCOONReusable Upper Torso Arms Out
Medicine Products: